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Канцерската болка е неиздржлива хронична јака болка која влијае врз квалитетот на животот на 
болните и претставува тежок здравствен, социјален и семеен проблем во многу земји. Светската 
здравствена организација (СЗО) предлага низа методи за нејзино сузбивање Епидуралната аналгезија 
со опиоиди е еден од предложените методи. Цел на трудот е да се утврдат ефектите на морфин, фен-
танил и буторфанол, употребени за епидурална аналгезија при неиздржлива болка, како и да се про-
коментираат искуствата од петгодишен период со осврт кон актуелноста на методот денес. Материјал 
и методи:  ретроспективна лонгитудинална опсервациска студија, спороведена на Универзитетската 
клиника за анестезија, реанимација и интензивно лекување, КАРИЛ,  Скопје, Република Северна Ма-
кедонија, во периодот помеѓу 2005-2010, со осврт на 2017-2018. Во студијата беа вклучени 116 болни 
кои страдаа од несносна канцерска болка, додека, пак, не беа вклучени болните со инфективни и 
метастатски процеси во ‘рбетот, алергија на опиоиди, психолошки проблеми и јазична бариера. Не-
посредно пред третманот, кај болните се евалуираше степенот на болката и тие беа рандомизирано 
одредени за аналгезија со еден од трите опиоида, кои се аплицираа преку епидурален катетер по-
ставен на височина Th8-10 или L2-3. Резултати: Со студијата се потврди дека степенот на болка пред 
третманот не се разликуваше меѓу трите групи (p>0,05). Се постигна сигнификантна аналгезија по 
15 минути во групата со буторфанол, по 20 минути со фентанил и по 30 минути со морфин (p<005). 
Времетраењето на аналгезијата буторфанол vs. фентанил vs. морфин беше 6 часа vs. 8часа vs. 24 часа. 
Со морфинот се постигна најдолга аналгезија (p<0,05). Заради зголемувањето на прагот на болката, 
со тек на време беше неопходно да се зголеми дозата на опиоидот. Најчесто реферирани несакани 
ефекти беа: чешање, констипација, уринарна ретенција и диспнеја, а отсуствуваа изјави за лошење 
и повраќање. Заклучок: Со оваа студија се потврди дека епидуралната аналгезија со опиоиди прет-
ставува ефикасен и сигурен метод за сузбивање на неиздржлива болка. Покрај другите алтернативи 
за третирање на канцерската болка, епидуралната аналгезија со опиоиди сèуште зазема еминентно 
место, а нејзината употреба е предизвик за професионалците. 
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Intractable cancer pain is a chronic severe pain, affecting patient’s quality of life and presents aheavy 
health, social and family problem in many countries. Different methods for pain relief are proposed 
by the WHO. Epidural analgesia with opioids is one of the proposed methods. Aim of the study 
was to determine the effects of morphine, fentanyl and butorphanol used for epidural analgesia in 
intractable pain and to comment our experiences over a five-year-period, with regard to its actuality 
nowadays. Material and methods: Retrospective longitudinal observational study was carried at the 
University Clinic for Anesthesiology, Reanimation and Intensive Care in Skopje, Macedonia, between 
2005-2010 and evaluated in 2017-2018. A total of 116 patients suffering from intractable pain were 
enrolled in the study. Exclusion criteria were: infective and metastatic processes in the spine, allergy 
to opioids, psychological problems and language barrier. After the pretreatment evaluation of the 
pain, patients were randomly assigned to receive three different opioids through epidural catheter 
placed from Th8-10 or L2-3. Results: There were no differences in pretreatment pain scores between 
the three groups (p>0.05). A significant onset of analgesia after 15 minutes was found for butorphanol, 
20 minutes for fentanyl and 30 minutes for morphine group (p<0.05). The duration of the pain relief 
of butorphanol vs. fentanyl vs. morphine was 6h vs. 8h vs. 24 hours respectively.  Morphine had the 
longest duration of pain relief (p<0.05). Because of an increase in the pain threshold, the need of an 
increase of opioid doses was necessary. The most often patient’s reports of side effects were: itching, 
constipation, urine retention and bradypnea and there were no reports of nausea and vomiting. 
Conclusions: It was concluded that epidural analgesia with opioids is an effective and safe method 
for suppression of intractable pain.  In spite of the other alternatives in treatment of cancer pain, 
epidural analgesia with opioids still has an eminent place and its use is a challenge for professionals.
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Introduction
Intractable cancer pain is a chronic 
severe pain, persisting at all times 
and affecting patient’s quality of life1. 
The patients with chronic cancer pain 
present heavy health, social and fami-
ly problem in our and other countries. 
Pain management of this group of pa-
tients has human and medical dimen-
sions2,3. For this reason, the World 
Health Organization (WHO) proposed 
“the analgesic ladder method” for 
pain relief of this group of patients.
The essences of this therapy are to give 
analgesics consecutively in order (lad-
ders). The first ladder is the use of non 
opioids, followed by mild opioids and at 
the end (the last ladder) are strong opi-
oids, until the patient is free of pain. For 
better pain relief drugs should be given 
“by the clock” (exact timing), with the 
use of “adjuvants” if it is necessary4,5. 
In such circumstances, to relieve in-
tractable pain, the use of epidural 
analgesia with opioid is one of the 
preferable methods.  The application 
of a minimal dose of opioids in the 
epidural space produces prolonged 
segmental analgesia without motor 
and sympathetic blockade6. The anal-
gesic effect is produced by acting on 
receptors located on neuronal cell 
membranes. The blocking effect of 
opioids in the spinal cord is on the 
level of “supstantia gelatinoza” where 
the opioids receptors are located. The 
major presynaptic action of opioids in 
the nervous system is to inhibit the re-
lease of neurotransmitters7.
This method for pain relief (epidural 
analgesia) has been used at our Clin-
ic since 1985. In the very beginning it 
was used as a method for treatment 
of postoperative pain, but very soon it 
became a superb method for pain re-
lief in intractable pain of patients who 
suffered from chronic cancer pain.
The aim of this study was to make a 
retrospective analysis of the effects 
of this old method of pain relief and 
to give a summary of our experience 
during a five-year-period, with regard 
to its actuality nowadays.
Material and methods
This study was conducted between 
2005-2010, at the University Clinic for 
Anesthesiology in Skopje R. Macedo-
nia. It was a part of the project “Devel-
opment of the patronage service for 
pain relief’”, in collaboration with the 
Hospice “Sue Rider” in Skopje. The de-
sign of the study was approved by the 
Ethics Committee of our Clinic. 
The study group consisted of 116 pa-
tients suffering from intractable pain, 
which during this period required in-
terventions in our outpatient clinic, 
where they were treated with epidur-
al application of opioids. 
The selection of patients was based 
according to the intensity and loca-
tion of the pain, the findings of the 
spinal cord and the acceptance of the 
patient to be treated with this meth-
od. The pain intensity at rest >70 mm 
on the Visual Analogue Scale (VAS), 
which lasted for more than 3 months, 
resistant to conventional therapy, was 
accepted as an intractable pain8. Pa-
tients with metastatic and infective 
processes in the spine, allergy to opi-
oids, psychological problems and lan-
guage barrier were excluded from the 
study.  A written signed consent was 
obtained from all patients included in 
this study. 
All patients were interviewed for main 
complaints, medical history and pain 
history. The information about diag-
nostic findings, results, analyses of 
laboratory tests and the screens were 
checked.  A complete physical exami-
nation of the patients was performed 
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and data about the previous analgesic 
interventions and drugs were noted. 
All enrolled patients (n=116) were informed 
about the procedure, educated about self-
injection, the use of 100mm Visual Ana-
logue Scale (VAS) and how to fill in the 
questionnaire specially designed for this 
study. The scheme of analgesic treatment 
was explained to all patients as well.
The procedure started with an evalu-
ation of the pain, according to the 
Visual Analogue Scale (VAS) and the 
opening of an intravenous (IV) line. All 
patients received IV infusion of 500 
mL of lactated Ringer’s solution prior 
to application of the epidural catheter 
(in sterile conditions). Depending on 
the health state of the patients, epi-
dural procedure was performed in a 
sitting or lying position. The injection 
was done using a 16 G Tuohy needle 
through which an appropriate cath-
eter was inserted. Depending on the 
origin of the pain, the epidural punc-
tures were at the level of Th8-10 or 
L2-3. The catheter was tunneled sub-
cutaneously on the upper direction 
with the aim to enable patient’s com-
fort and to avoid superinfection9. The 
test dose of 3ml 0.5% bupivacaine was 
inserted and the sensory was checked; 
after a negative response at 5 min, 
without loss of sensation, an applica-
tion of opioid was performed. 
The starting dose for epidural appli-
cation was as follows: morphine 3mg 
with 8 ml diluents, fentanyl 30 μgr 
with 10 ml diluents or 1 mg metha-
done with 9 ml diluents.
After the daily evaluation of the pain, 
the doses were adjusted with the an-
algesic needs of the patients, and the 
addition doses of the epidural opioid 
or oral analgesic were prescribed.
The level of pain, the onset and the 
duration of the pain relief, the need 
for additional doses of analgesics dur-
ing a 4-week-period and the side ef-
fects were noted in the questionnaire. 
The numerical data in the study were 
statistically elaborated by using mean, 
standard deviation and the paired 
Student’s t-test. Mann Whitney U test 
was used as additional statistics. A p 
value of < 0.05 was considered to indi-
cate a statistical significance.
Results
The basic demographics of the includ-
ed patients are presented in Table 1. 
Table 1.  Demographic distribution of patients (M±SD)
Period of time Number of patients Age Weight
Male Female Kg/
2005-2006 3 2 57±2 64±7
2006-2007 19* 2 62±10 69±5
2007-2008 15* 13* 64±7 58±11
2008-2009 22* 9 61±3 49±8
2009-2010 30* 3 63±7 55±9
Total 87 29
5 years 116 patients 61±4 59±5
 * p<0.05
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During the five-year-period, 116 pa-
tients with cancer pain were treated 
with regional analgesia through epi-
dural application of opioids. The dis-
tribution by sex was 87 males and 29 
females, hence, the predomination 
of male patients was obvious. A small 
group of patients was included in the 
first year, but in the following years 
this number was statistically signifi-
cantly increased (p<0.05).
Table 2 presents the distribution of the 
patients according to the diagnosis and 
the level of the epidural puncture. 
The main cause of the pain, in most 
of the treated patients, was the grade 
of the carcinoma after surgery, or an 
inoperable state of the carcinoma in 
the lower abdomen more often than 
in other locations (90 vs.26) (p<0.05).
According to 100 mm VAS, the pain 
was evaluated in pain scores. In Table 3 
the results of the pain scores obtained 
on the first day of treatment are pre-
sented. The primary level of pain was 
checked, and after the application of 
the drugs, the onset and the duration 
of the pain relief were measured. 
Period of time Number of patients Age
Low abdomen:
• Ca rectum
• Ca colon
• Ca urinary bladder
90 (77.58%)*
Th 10-L1
Th9-L1
L2-L4
Inoperative Ca of the lungs 14 (12.04%) Th 8-10
Other locations 12 (10.34%) L2-L3
* p<0.05
Drug
Time
t 0
15
min
30
min
6h 12h 18h 24h
Morphine 3mg
(n=87) 80.7±7.3 39.19±9.4 18.3±4.8* 17.9±5* 18.4±5.1* 44±7.3 61.1±11.4
Fentanyl 
30 µg
(n=26) 81.8±7.4 34.1±5.6 22.4±4.1* 29.2±9.3 64.7±17.6
Butorphanol 
1mg
(n=3)
79±2.9 26.3±5.3* 19±5.2* 50±10.8 72.3±2.0
Difference NS *p< 0.05
Table 2.  Diagnosis and level of epidural puncture (n=116)
Table 3.  First day pain evaluation and analgesic efficiency-VAS (M±SD)
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Drug Patients
1st 
dose
2nd week
3rd
week
4th 
week
Analgesia (h)
Morphine 87 (75%) 3 mg 5 mg 7 mg 8 mg 24 h
Fentanyl 26 (26.5%) 30 µg 2x 30 µg 2x 30 µg 2x 30 µg ≈10 h
Butorphanol 3 (2.5%) 1mg 3x 4x 4x 6.5h
Total 116 (100%)
B u p i v a c a i n e 
0.125% 13 (15%)
 As adjuvant, local anesthetic 0.125% bupivacaine was used in 15% of the patients. 
Table 4.  Doses of epidural opioids used in the four-week-period
It was obvious that at time zero (t 0), 
the primary measured level of pain be-
tween the different drug groups was 
insignificant (p>0.05).  
The onset of the pain relief started 
after 15 minutes with a peak effect 
reached after 30 minutes.  A significant 
onset of analgesia after 15 minutes was 
found for butorphanol, 20 minutes for 
fentanyl and 30 minutes for morphine 
group (p<0.05). A significant positive 
analgesic effect after 30 minutes was 
established for morphine, fentanyl and 
butorphanol (p<0.05).  The duration of 
analgesia lasted 4-6 hours for butorph-
anol, 8-10 hours for fentanyl and 18-24 
hours for morphine (Table 4). 
Table 4 presents the results over the 
four-week-period with the doses of 
medications given in the epidural 
space. 
In the analyzed material, it was found 
that morphine was the favorable drug 
for most of the patients (75%), followed 
by fentanyl (26.5%) and butorphanol 
(2.5%). In this four-week-period the 
dose of morphine increased from 3 to 
8 mg per day; a multiplication of the 
dose of fentanyl from one to two times 
per day was established and three to 
four times per day for butorphanol.
According to the duration of the epi-
dural treatment the doses of applica-
tion of the drug were increased suc-
cessively. The patients were educated 
for self-application of the medication 
in the epidural catheter. 
In the first week of the treatment, the 
first dose was satisfactory for 89% of 
the treated patients with analgesia 
from 6-24 hours depending on the 
drug. After seven days of treatment, 
the first signs manifested that the 
threshold of the pain was increased, 
and consecutively the doses of the 
opioids were increased or exchanged 
by another drug.  
In our series, in 78% of the treated pa-
tients with morphine, the dose of 3 mg 
epidural morphine was increased to 5 
mg, in 10% the dose was increased to7 
mg given in 24h; in 12% of patients the 
dose of morphine was 8mg/24 h or it was 
substituted by fentanyl or butorphanol.
The duration of the epidural treat-
ment lasted from 30 to 60 days. The 
treatment was interrupted because of 
the development of complications or 
because of the end of the life.
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The most often seen side effect was 
itching, which was present in the 
three used opioids. Urinal retention 
was less present than expected, but 
most of the patients were with urine 
catheters. Also, constipation was 
present in small numbers, because it 
was prevented with the use of bupi-
vacaine 0.1%. Two patients who devel-
oped local infection were shifted to 
other treatment and excluded from 
the study.  
Discussion
Opioids are important drugs used in 
the pain relief management. The re-
gional analgesia with opioids proba-
bly achieved the veritable point of the 
WHO’s pain relief ladder suggestion 
for a “freedom in the treatment of 
cancer pain” 10, 11.
The fundamental discovery in1977 
by Jaksh TL and Rudy TA that opioid 
receptors are located in substantia 
gelatinosa in dorsal corns of the spi-
nal cord, announced a new era in the 
treatment of pain on segmental lev-
el12, 13. The small dose of opioids given 
in the epidural space has prompted 
analgesic reaction, without sedation, 
unwanted central sensory effects like 
drowsiness and euphoria. Morphine 
is a ‘gold-standard’ single-dose epi-
dural opioid due to its analgesic ef-
ficacy and prolonged duration of ac-
tion. 
However, the risks of development of 
side effects like itching, nausea and 
vomiting, urinary retention, constipa-
tion and, the most important, respira-
tory depression are not excluded 14. 
The retrospective critical analyses 
of the results obtained have shown 
that the method of epidural analge-
sia with opioids provided successful 
pain relief. The development of side 
effects was in the ranges of the an-
ticipations. The effects of opioids on 
respiration were only with the devel-
opment of bradipnea.  Respiratory ar-
rest was not perceived in this group. 
We speculate that the main reason 
for this was the use of small doses of 
narcotics, and secondly, the use of di-
luents as well as the intact durra in-
sured by the pretreatment test dose.  
Several authors studied the reasons 
for development of respiratory de-
Side effect
Morphine
(n=87)
Fentanyl
(n=26)
Butorphanol
(n=3)
Bradipnea 4 (4.5%)* 0 0
Itching  85 (97.7%) 25(96.7%) 2
Urine retention 14(16%) 13(50%)* /
Constipation 17(19.5%) 4 (15.38%) /
Local infection 2(2.2%) / /
Nausea/vomiting 2(2.2%) / /
Drowsiness / / /
Allergy / / /
 *p< 0.05
Table 5.  Side effects after epidural application of opioids (N/%)
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pression after epidural administra-
tion15-17. Most of them agree that the 
migration of opioids in intrathecal 
space could be one of the possible 
reasons for incidents with respira-
tory depression18,19. First of all, the 
explanation was that opioids in the 
cerebrospinal fluid interac with opi-
oid receptors in ventral medulla. Lat-
er studies have shown that the main 
places of activity are neurons of the 
pre-Bötzinger complex in the me-
dulla as mediators of opioid-induced 
respiratory depression, where the 
expressing neurokinin-1 receptors 
are selectively inhibited by opioids 20. 
Other authors have found that the 
development of respiratory depres-
sion is more specific for opioids ago-
nists connected to mu-receptors, and 
its lipo-solubility. Therefore, accord-
ing to the ASA guidelines, all partici-
pants in this study, prior to epidural 
treatment, were submitted to a seri-
ous identification for possible risk 
factors 21, 22.
We can conclude that in our series 
the number of treated patients was 
not high. We believed that it was due 
to the disbelief of some of the pa-
tients; for some of them the meth-
od was too aggressive, or they were 
scared, and some of the patients were 
not prepared for self-treatment. Ad-
ditionally, general practitioners were 
not informed about the possibility for 
epidural treatment of the pain.
The number of the treated patients 
from year to year has increased sig-
nificantly (p<0.05). The efficacy of the 
pain relief treatment has been suc-
cessful in 99% of the patients. The 
use of VAS for evaluation of the pain 
may be not the appropriate method, 
but it is simple and accurate and is 
very easy and well accepted by the pa-
tients 23-26.
The main findings are that good an-
algesic effects are related to the close 
relationship of the therapist and the 
patient and achieved confidence be-
tween them. 
The main benefits of the epiduraly 
applied opioids are good analgesia, 
improved quality of life and physi-
cal function. The therapy must be 
balanced against the risks of side ef-
fects27, 28.
This five-year experience showed 
that the method of epidural analge-
sia with opioids was and still is an 
alternative among the methods for 
treatment of the intractable pain in-
patients with carcinoma. 
This method was very popular in the 
1990’s. The development of less ag-
gressive methods for pain relief, such 
as fentanyl patch, patient control an-
algesia (PCA), the prescriptions of oral 
opioids and other strong analgesics 
from non-opioids origin, suppressed 
epidural analgesia as the main pain 
relief method 29. The establishment 
of medical cannabis as an alternative 
therapy in cancer pain opens a new 
way in the management of intracta-
ble pain. 
Today, epidural analgesia has an ul-
timate place in pre-emptive analge-
sia, during regional and general an-
esthesia and in the variety of “opioid 
spearing techniques” that can reduce 
the postoperative pain and shorten 
the recovery period after surgery. 
This was documented in several tri-
als and it was concluded that regional 
techniques used as pre-emptive ther-
apy, before the pain appears, lead to 
a decreased need of opioids for anal-
gesia 30.  
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The main side effect that discredited 
the use of epidural analgesia with 
opioids was the development of con-
stipation. Continual assessment of 
the efficacy and tolerance of the drug 
is essential. Liu SS. with his team in 
1995 compared 4 studies about the 
epidural bupivacaine with epidural 
opioid, and 3 of these studies dem-
onstrated a significant reduction in 
the duration of postoperative ileus in 
the epidural bupivacaine group com-
pared tothe epidural opioid group31,32. 
This was the reason for using epidur-
al bupivacaine (0.125%) in small doses 
which showed successful results as 
adjuvant 33. 
Today, there are different analgesic 
modalities as “opioid spearing tech-
niques” which are used often and have 
minimal impairment of GI function. 
The concept of a multimodal analge-
sic program in which pain relief is a 
key factor is a major task for the fu-
ture. The pain management strategy 
in multimodal protocols is using epi-
dural analgesia, ketamine, acetamin-
ophen, gabapentin and COX-inhibi-
tors. These concepts ensure that the 
“era” of epidural analgesia is still ac-
tual for pain management in patients 
with intractable cancer pain 34.
Conclusion
It can be concluded that the forgotten 
method of epidural analgesia with 
opioids for the treatment of cancer 
pain should be revised. It seems that 
it is still the most efficient method 
to suppress the intractable pain. It 
is with a prompt and long duration 
analgesic effect. Epidural analgesia 
with opioids is an effective and safe 
method for suppression of intrac-
table pain. In addition to the other 
alternatives in treatment of cancer 
pain, epidural analgesia with opioids 
still has an eminent place and its use 
is a challenge for professionals.
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